COMy 2024 | The role of cilta-cel in the myeloma treatment landscape
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the role of ciltacabtagene autoleucel (cilta-cel) in treating myeloma. Currently utilized in the relapsed/refractory (R/R) setting, cilta-cel has achieved a median progression-free survival (PFS) of approximately three years. The CARTITUDE-4 study (NCT04181827) is exploring its use in earlier therapy lines. Dr Martin highlights the advantage of cilta-cel’s single-infusion administration, allowing patients a break from continuous medication. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
